AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection
Published: 29 October 2024
-
Views:
2102
-
Likes:
7
-
Views:
2102
-
Likes:
7
-
Up Next -
17m 22sPart 2 | Session 3 SUMMIT: Tirzepatide in Patients with HFpEF and Obesity -
16m 57sPart 2 | Session 4 FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk -
22m 30s
-
6m 17s -
3m 53s -
7m 19sPart 3 | Session 3 Mavacamten: Real-World Experience from 22 Months of the REMS Program -
10m 31s -
4m 41sPart 3 | Session 5 EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure -
6m 53s -
5m 6sPart 3 | Session 7 NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy -
5m 7s -
4m 30sPart 3 | Session 9 ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF -
3m 49s -
5m 28sPart 3 | Session 11 ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients -
3m 44sPart 3 | Session 12 BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH -
3m 40sPart 3 | Session 13 KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients -
Part 3 | Session 14 OPTION: LAA Closure with Oral Anticoagulation after AF Ablation
-
13m 43sPart 1 View from the Thoraxcenter: AHA 24 Late-breaking Preview Joost Daemen, Nicolas M Van Mieghem
-
29m 32sPart 2 | Session 1 ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Harriette Van Spall, Kausik Ray
Overview
Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.
- To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
- Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
- Don't miss the key take aways from our Highlights series.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Expert Interviews
Part 4
Highlights
About the episode
AHA Conference 2024 — New insights from the NUDGE-FLU Program on electronic nudges to increase influenza vaccination amongst patients with a history of myocardial infarction.
Dr Harriette Van Spall (McMaster University, CA) sits down with the principal investigator of the NUDGE-FLU trial, (NCT05542004) Dr Tor Biering-Sørensen, to discuss the latest insights and data.
NUDGE-FLU is a prospective, randomized, open-label implementation trial investigating the impact of electronic nudges on influenza vaccine uptake amongst eligible candidates. This research specifically investigated the outcomes of NUDGE-FLU in a cohort of patients with a history of myocardial infarction, exploring the effects of electronic, letter-based nudges as compared to usual care on influenza vaccine uptake by history of AMI. In the study, AMI was defined as an overnight hospitalization with ICD-10.
Findings showed that in a pooled analysis of 3 randomized trials with less than 2 million patients across a Danish population, electronic nudges emphasising the cardiovascular benefits of influenza vaccination improved uptake. This was particularly effective in patients with a history of AMI.
Recorded remotely from Hamilton, CA and Copenhagen, DK.
Editors: Jordan Rance and Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Tor Biering-Sørensen
Associate Professor and the Director of Cardiac Imaging
Dr Tor Biering-Sørensen is an Associate Professor and Director of Cardiac Imaging at the Copenhagen University Hospital Herlev, with a focus on advancing cardiovascular imaging techniques for early diagnosis of cardiac impairment to prevent future morbidity and mortality. He is the Head of Center for Translational Cardiology and Pragmatic Randomised Trials and the Head of the Cardiovascular Non-Invasive Imaging Research Laboratory, both renowned for their innovative research.
Holding a medical degree and a PhD from the University of Copenhagen, a Master of Public Health from Harvard, and a Master of Science in Clinical Trials from Oxford, Dr. Biering-Sørensen is a distinguished academic. He has published over 350 scientific articles and received several prestigious research awards internationally.
He actively mentors medical and PhD students, guiding them in cardiovascular imaging. His research also involves conducting large-scale pragmatic randomised trials using…
Comments